Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication

Incidence of adverse effects

According to the requirements of the "Drug Clinical Trial Management Code", the observation is carried out, and the adverse reactions of the patients during the administration of the drug are recorded. The severity, or intensity, of an AE refers to the extent to which an AE affects the subject' s daily activities. The intensity of the AE will be rated as mild (discomfort without influencing daily activities), moderate (discomfort partially influencing daily activities), or severe (discomfort with severe interruption with daily activities).

Time frame: 14 days of treatment, and 28 days after treatment

Treatment compliance

Adherence was analysed according to medication possession ratio (MPR), where taking less than 80% of study drug during any evaluation period or failure to review was considered poor adherence;

Time frame: 7 or 14 days of treatment

Symptom relief rate

Patients were classified as no change, remission, cure, or exacerbation based on changes in clinical symptoms.

Time frame: 14 days of treatment, and 28 days after treatment